.png){kind=icon}
.png){kind=icon}
Return
Cryptococcal meningoencephalitis: time for action
.png){kind=icon}
OA
AI
DOI：10.1016/S1473-3099(20)30771-4.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Cryptococcal meningoencephalitis was first described over a century ago. This fungal infection is preventable and treatable yet continues to be associated with excessive morbidity and mortality. The largest burden of disease resides in people living with HIV in low-income and middle-income countries. In this group, mortality with the best antifungal induction regimen (7 days of amphotericin B deoxycholate [1 center dot 0 mg/kg per day] and flucytosine [100 center dot 0 mg/kg per day]) in a clinical trial setting was 24% at 10 weeks. The world is now at an inflection point in terms of recognition, research, and action to address the burden of morbidity and mortality from cryptococcal meningoencephalitis. However, the scope of interventional programmes needs to increase, with particular attention to implementation science that is specific to individual countries. This Review summarises causes of excessive mortality, interventions with proven survival benefit, and gaps in knowledge and practice that contribute to the ongoing high death toll from cryptococcal meningoencephalitis.
Keywords:
RECONSTITUTION INFLAMMATORY SYNDROME
HIV-INFECTED PATIENTS
STARTING ANTIRETROVIRAL THERAPY
EARLY FUNGICIDAL ACTIVITY
CEREBROSPINAL-FLUID
AMPHOTERICIN-B
INTRACRANIAL-PRESSURE
ANTIFUNGAL THERAPY
COMBINED COHORT
FUNGAL BURDEN
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
31
Papers:
7.9K
Citations:
4.0W
View more organizations